CBD Oil Research

At this time, the Food & Drug Administration (FDA) has only approved CBD oil for epilepsy in children. It is inappropriate to make any health claims about CBD Oil until further studies have been done.

  • More than 10,000 research studies have been done with CBD oil and the results are very promising.
  • You can read the results of these research studies for yourself at the links below: 

https://www.ncbi.nlm.nih.gov/pmc/?term=cbd


Review of the neurological benefits of phytocannabinoids

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938896/

Results: 

  • Recent neurological uses include adjunctive treatment for malignant brain tumors, Parkinson's disease, Alzheimer's disease, multiple sclerosis, neuropathic pain, and the childhood seizure disorders Lennox-Gastaut and Dravet syndromes.
  • In addition, psychiatric and mood disorders, such as schizophrenia, anxiety, depression, addiction, postconcussion syndrome, and posttraumatic stress disorders (PTSD) are being studied using phytocannabinoids.

ConclusionAlthough federal and state laws are inconsistent about the legality of cannabis production, its increasingly documented health benefits make it once again relevant in medicine. Current research indicates the phytocannabinoids have a powerful therapeutic potential in a variety of ailments primarily through their interaction with the ECS. CBD is of particular interest due to its wide-ranging capabilities and lack of side effects in a variety of neurological conditions and diseases.

  • Very low toxicity of CBD in humans. Unlike the psychoactive properties associated with Δ9-THC, CBD has been shown to have very low toxicity in humans and in other species (see Safety section). Ingested and absorbed CBD is rapidly distributed, and due to its lipophilic nature can easily pass the blood–brain barrier. The terminal half-life of CBD is about 9 h and is preferentially excreted in the urine as its free and glucuronide form.

  • SafetyA comprehensive safety and side effect review of CBD in 2016 on both animal and human studies described an excellent safety profile of CBD in humans at a wide variety of doses. The most commonly reported side effects were tiredness, diarrhea, and changes of appetite/weight. In studies comparing other medicinal drugs used for the treatment of these medical conditions, CBD also had a very favorable side effect profile. CBD does have interactions with common hepatic (drug)-metabolizing enzymes, belonging to the cytochrome P450 family. Therefore, interactions with drug transporters and interactions with drugs must be considered.

  • CBD – better safety profile vs. other cannabinoids. CBD also has a better safety profile compared to other cannabinoids, such as THC. For instance, high doses of CBD (up to 1500 mg/day) are well tolerated in animals and humans. In contrast to THC, CBD does not alter heart rate, blood pressure, or body temperature, does not induce catalepsy, nor alter psychomotor or psychological functions. This improved safety profile may be a result of its lack of direct agonist properties at cannabinoid receptors. 

  • Conditions and Diseases in Which Activation of The ECS (Endocannibinoid System) has Shown Benefit:

tabled

Mecha M, Feliú A, Carrillo-Salinas F, Guaza C. Handbook of Cannabis and Related Pathologies. Elsevier; 2017. pp. 893–904.


Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161644/

  • Anti-parkinsonian (Parkinsons)
  • anti-oxidative actions (antioxidant)
  • Neuroprotective and neuroplasticity increasing drug protects the brain from effects of aging. 
  • Anti-epileptic action
  • Sleep disorders
  • Addiction
  • Mood stabilization

Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4851925/

Conclusions: These data indicate that topical CBD application has therapeutic potential for relief of arthritis pain-related behaviours and inflammation without evident side-effects.


Cannabidiol in Humans—The Quest for Therapeutic Targets

Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, is attracting growing attention in medicine for its anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties. However, up to this point, a comprehensive literature review of the effects of CBD in humans is lacking. 

Keywordscannabidiol, THC, cannabis, multiple sclerosis, pain, social anxiety disorder, epilepsy, insomnia, schizophrenia

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763649/


Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710104/


Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes (acne)

The endocannabinoid system (ECS) regulates multiple physiological processes, including cutaneous cell growth and differentiation. Here, we explored the effects of the major nonpsychotropic phytocannabinoid of Cannabis sativa, (-)-cannabidiol (CBD), on human sebaceous gland function and determined that CBD behaves as a highly effective sebostatic agent. ... Collectively, our findings suggest that, due to the combined lipostatic, antiproliferative, and antiinflammatory effects, CBD has potential as a promising therapeutic agent for the treatment of acne vulgaris.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4151231/